LSE - Delayed Quote GBp
Genus plc (GNS.L)
1,606.00
-12.00
(-0.74%)
At close: April 22 at 4:36:08 PM GMT+1
Breakdown
TTM
6/30/2024
6/30/2023
6/30/2022
6/30/2021
Operating Cash Flow
29,800
29,800
50,400
34,300
67,500
Investing Cash Flow
-19,300
-19,300
-30,900
-67,200
-46,700
Financing Cash Flow
-2,800
-2,800
-18,200
21,900
-14,200
End Cash Position
42,500
42,500
36,300
38,800
46,000
Capital Expenditure
-24,700
-24,700
-35,200
-65,400
-33,800
Issuance of Capital Stock
100
--
--
--
100
Issuance of Debt
140,400
140,400
126,800
138,700
195,100
Repayment of Debt
-108,500
-108,500
-111,700
-83,900
-176,100
Free Cash Flow
5,100
5,100
15,200
-31,100
33,700
6/30/2021 - 7/6/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ONTl.XC
TRX.L Tissue Regenix Group plc
36.40
-0.27%
RGLS Regulus Therapeutics Inc.
2.3200
+15.42%
SXTP 60 Degrees Pharmaceuticals, Inc.
2.6700
-15.51%
BMEA Biomea Fusion, Inc.
1.9500
+13.37%
NTLA Intellia Therapeutics, Inc.
8.31
+4.92%
VRTX Vertex Pharmaceuticals Incorporated
490.47
+2.71%
CRSP CRISPR Therapeutics AG
39.23
+3.73%
VKTX Viking Therapeutics, Inc.
25.48
+7.42%
MRNA Moderna, Inc.
25.74
+2.43%